Analysts at StockNews.com assumed coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Get Free Report) in a research report issued to clients and investors on Tuesday. The firm set a “sell” rating on the biopharmaceutical company’s stock.
Akari Therapeutics Trading Up 0.3 %
Shares of AKTX stock opened at $2.95 on Tuesday. Akari Therapeutics has a 52 week low of $1.08 and a 52 week high of $4.40. The company’s fifty day simple moving average is $3.54 and its two-hundred day simple moving average is $2.61.
Akari Therapeutics Company Profile
Read More
- Five stocks we like better than Akari Therapeutics
- How to Most Effectively Use the MarketBeat Earnings Screener
- TJX Stock: A Buying Opportunity Before the Holiday Rush
- How to Use Stock Screeners to Find Stocks
- Micron’s Blowout Results Pave the Way for Seagate’s Stock Surge
- 3 Fintech Stocks With Good 2021 Prospects
- Zeta Global’s AI Cloud: Your Secret Weapon for Massive Growth
Receive News & Ratings for Akari Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.